Pharma

By Laura Lovett 11:52 am June 11, 2019
Less than a year after the blockchain-enabled genome sequencing startup's launch, Nebula Genomics is announcing its first pharma partnership with Merck KGaA’s EMD Serono. This early partnership will come in the form of a pilot program.  As part of the deal, EMD Serono will be able to use Nebula’s network of anonymized genomic data. This new pilot is specifically zeroing in on lung cancer patients...
By Dave Muoio 03:52 pm June 5, 2019
Healthcare is in the midst of a digital shift. Artificial intelligence offers physicians providers an new resource when making decisions, new data streams promise hyper-personalized treatments and digital therapeutics evangelists see are hawking the novel treatments as a companion, or even a replacement, to traditional biologic treatments. All in all, it’s a future that hopes to empower the...
By Tammy Lovell 05:31 am June 5, 2019
“Currently health and tech don’t speak the same language,” says Erik Janssen, vice president of innovative solutions neurology at biopharma company UCB. In order to benefit from the value technology can bring to patients, Janssen believes that pharma must adapt its approach. While pharma is a heavily-regulated industry which tends to work in siloes, tech companies tend to be much more “...
By Dave Muoio 12:09 pm June 4, 2019
Since it was first announced, fans and critics of the FDA’s Pre-Cert program for medical software developers have mused on the benefits and burdens that might come with participation in the experimental program. What to expect from Pre-Cert The question has only become more pertinent since the agency released its 1.0 Working Model in January and, just a couple weeks ago, began seeking new De Novo...
By Laura Lovett 01:23 pm May 28, 2019
Wearable sensor maker MC10 is teaming up with biopharma company AbbVie on a new set of multiple sclerosis (MS) clinical trials. The pair plan to use MC10’s FDA cleared wearable sensor technology, dubbed the BioStamp nPoint system, to help keep track of a patient’s physiological data and outcomes during the trials.  The flexible and stretchable electronic sensors landed FDA clearance last year to...

 (Left to right) Nathan Treloar, Sarah Lindenauer and Matteo Lai at the MassBio panel in Cambridge, MA. 

By Laura Lovett 03:11 pm May 22, 2019
Virtual assistants and wearable technologies are starting to catch the pharma world’s attention. The industry is exploring how the new tools can be used in research, clinical trials and inpatient settings. However, obstacles including privacy compliance and data standards are still questions that the industry is grappling with, according to panelists at the MassBio forum on Using Clinical Data...
By Laura Lovett 10:23 am May 21, 2019
This morning, artificial-intelligence-enabled monitoring and decision support platform Biofourmis announced a $35 million Series B raise. The round was led by Sequoia India and MassMutual Ventures with participation from EDBI, Jianke and existing investors Openspace Ventures, Aviva Ventures and SGInnovate.  The funding announcement coincided with the news that the Singaporean company will be...
By Dave Muoio 10:03 am May 21, 2019
This morning Verily announced a series of new strategic partnerships with four global pharmaceutical companies that will bring low-burden digital data collection and analysis tools to clinical research projects. Alongside Novartis, Otsuka, Pfizer and Sanofi, the Alphabet subsidiary will employ its Project Baseline platform to increase the number and diversity of study populations by making it...
By Dave Muoio 02:32 pm May 16, 2019
Express Scripts will be releasing a stand-alone formulary in 2020 that highlights vetted digital health tools for the pharmacy benefit management firm’s payer and consumer customers, according to an announcement released this morning. The company said that it will be treating the new formulary in much the same way it would a similar resource for traditional medications. To be included, a digital...
By Joe Slavinsky 01:58 pm May 16, 2019
About the author: Joe Slavinsky leads business development efforts with pharmaceutical, biotechnology and medical technology companies in his VP position at Propeller Health. A former epidemiologist, he worked at a hedge fund (Citadel) and an investment bank (Thomas Weisel Partners) as an equity research analyst covering small/mid-cap biotechnology companies. Joe joined Propeller from Gilead...